Bloomage BioTechnology Corporation Limited (SHA:688363)
China · Delayed Price · Currency is CNY 37.45
-1.12 (-2.90%)
Aug 14, 2026, 3:00 PM CST
SHA:688363 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 17,915 | 20,895 | 24,416 | 32,239 | 65,081 | 74,544 | |
Market Cap Growth | -30.13% | -14.42% | -24.27% | -50.46% | -12.69% | 6.06% |
Enterprise Value | 17,274 | 20,429 | 24,211 | 31,288 | 63,593 | 73,055 |
Last Close Price | 37.45 | 43.45 | 50.66 | 66.04 | 132.59 | 151.63 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 69.51 | 71.54 | 140.10 | 54.41 | 67.03 | 95.28 |
Forward PE | 42.99 | 38.61 | 34.88 | 29.56 | 51.50 | 90.88 |
PS Ratio | 4.53 | 4.98 | 4.55 | 5.31 | 10.23 | 15.07 |
PB Ratio | 2.50 | 2.94 | 3.57 | 4.62 | 9.74 | 13.07 |
P/TBV Ratio | 2.78 | 3.27 | 3.97 | 5.20 | 11.01 | 14.43 |
P/FCF Ratio | 39.81 | 69.24 | - | - | - | 151.56 |
P/OCF Ratio | 22.93 | 33.30 | 43.25 | 46.08 | 102.46 | 58.42 |
PEG Ratio | - | 1.22 | 1.22 | 1.22 | 1.35 | 1.98 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 4.37 | 4.87 | 4.51 | 5.15 | 10.00 | 14.77 |
EV/EBITDA Ratio | 30.90 | 37.99 | 51.34 | 40.35 | 56.57 | 84.27 |
EV/EBIT Ratio | 89.40 | 86.85 | 104.19 | 54.87 | 66.14 | 97.87 |
EV/FCF Ratio | 38.39 | 67.70 | - | - | - | 148.53 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.06 | 0.05 | 0.05 | 0.03 | 0.06 | 0.05 |
Debt / EBITDA Ratio | 0.71 | 0.58 | 0.68 | 0.25 | 0.33 | 0.33 |
Debt / FCF Ratio | 0.88 | 1.13 | - | - | - | 0.61 |
Net Debt / Equity Ratio | -0.09 | -0.10 | -0.06 | -0.16 | -0.26 | -0.41 |
Net Debt / EBITDA Ratio | -1.31 | -1.28 | -0.83 | -1.42 | -1.55 | -2.71 |
Net Debt / FCF Ratio | -1.49 | -2.28 | 2.48 | 3.33 | 28.54 | -4.78 |
Asset Turnover | 0.46 | 0.48 | 0.63 | 0.71 | 0.79 | 0.75 |
Inventory Turnover | 1.22 | 1.21 | 1.24 | 1.45 | 1.59 | 1.89 |
Quick Ratio | 1.42 | 1.38 | 1.00 | 1.47 | 1.61 | 2.20 |
Current Ratio | 2.36 | 2.34 | 2.04 | 2.56 | 2.45 | 2.85 |
Return on Equity (ROE) | 3.61% | 4.17% | 2.44% | 8.53% | 15.52% | 14.47% |
Return on Assets (ROA) | 1.40% | 1.70% | 1.70% | 4.15% | 7.42% | 7.06% |
Return on Invested Capital (ROIC) | 2.84% | 3.19% | 2.97% | 8.75% | 19.64% | 20.72% |
Return on Capital Employed (ROCE) | 2.60% | 3.10% | 3.20% | 7.90% | 13.70% | 12.20% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 1.42% | 1.40% | 0.71% | 1.84% | 1.49% | 1.05% |
FCF Yield | 2.51% | 1.44% | -0.64% | -1.03% | -0.09% | 0.66% |
Dividend Yield | 0.51% | 0.44% | 0.22% | 0.57% | 0.46% | 0.32% |
Payout Ratio | 22.27% | 19.20% | 106.69% | 51.55% | 25.01% | 25.69% |
Buyback Yield / Dilution | 2.70% | 1.09% | -0.48% | 0.27% | -0.03% | -0.95% |
Total Shareholder Return | 3.20% | 1.53% | -0.27% | 0.84% | 0.43% | -0.62% |